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Optimal use of staging data in international comparisons of colorectal cancer survival 
Dear Editor, 
We welcome the comments by Eden et al. (1), which provide an opportunity to discuss the 
complex issue of international comparisons of survival by stage at diagnosis (2). It is simply 
not the case that we compared exclusively pathological data on Dukes’ stage from the UK 
with optimally integrated data on stage from other countries, as Eden et al. suggest. Eden et 
al. assert that we “have principally misinterpreted the origins and composition of the data 
used in [the] analysis”. We strongly disagree. An expert committee of cancer registry 
directors and senior colorectal oncologists in each country was actively involved at every 
stage of this study, from protocol design to data quality control, analysis, interpretation and 
drafting, together with us, under the direction of an international Programme Board.  
We were aware of the caveats highlighted by Eden et al., and we took great care to examine 
the pathological (p) and clinical (c) origins of the stage data for every patient in these data 
sets. We defined an algorithm such that Dukes’ stage was determined via the component pT, 
pN and cM values, wherever possible. We also noted the possible biases and differences that 
can arise if only the ‘grouped’ Dukes’ stage was available. This is described in the ‘methods 
paper’ that accompanied our analyses (3). We acknowledged in that paper that some 
inconsistencies remained, and we reiterated it in the colorectal cancer paper (2). It is precisely 
because of the “limitations of this methodology” that we presented two sets of analyses, one 
based on SEER Summary Stage 2000 and another based on Dukes’ stage. 
Table 1 below shows the origin of the final stage data used in the survival analyses. Among 
patients with a valid stage (defined in (3)), we give the proportions of patients whose final 
stage was specified on the basis of component T, N and M codes supplied by the registry. 
Among those, we show the origin of those variables as either pathological, clinical or 
unknown. If one of the component codes is shown as of ‘unknown’ origin, it means the 
registry did not indicate whether the value provided was based on pathological or clinical 
evidence: it may thus reflect either a value that had been deliberately integrated by the source 
registry as the best reflection of the stage on the basis of all available data, or that the 
pathological or clinical origin of the value was actually unknown. It was not possible to 
distinguish between these scenarios from the available data or from discussion with the 
registries. 
The proportion of rectal cancer patients for whom component T, N and M codes were 
supplied was 0% in Norway. In Sweden, the proportion was just over 30% for both colon and 
rectal cancer, compared to just under 20% in the UK – not a great difference. Among those 
patients for whom T, N and M codes were available, the UK had relatively low proportions of 
pT, pN and cM codes (the optimal values). Where T, N and M codes were available for 
patients with colon or rectal cancer, their origin was unknown for about one-third (27-35%) 
of patients in the UK, but this proportion reached 90-100% of patients in Denmark and 
Sweden. 
Eden et al.’s description of how stage was defined in the ICBP study is simplistic. They 
assume that we based our final stage variable on pathological Dukes’ stage alone, although as 
shown in Table 1, the picture is more complex. Wherever possible, we used much more 
detailed information. 
Eden et al. exemplify their doubts with a combined analysis of patients diagnosed with either 
colon or rectal cancer in 2011, in one region of England with good data on stage, ignoring 
patients with missing stage data. Those patients were diagnosed 4-11 years later than the 
patients in this ICBP study (2000-2007), which covered most of England. Moreover, the 
“ICBP-like” distribution of stage in their Figure 1 is not even close to the distribution we 
published (e.g. 2% metastatic, cf. 16.9% in the ICBP study). It is not an accurate description 
of the data we analysed. 
 
Their distribution of “ICBP-like stage” for colon and rectal cancers combined is closer to the 
distribution in the ICBP study for those patients whose stage was based solely on a Dukes’ 
stage variable (Table 2). The relatively low proportion of metastatic disease among these 
patients because of pathological Dukes’ staging was noted very early in the ICBP study: it 
was the subject of correspondence with scientists in the English cancer registries, including 
Dr Rous. When patients whose final stage was constructed from the component T, N and M 
codes are included, the overall proportion with metastatic disease in the ICBP study (17%) is 
similar to the proportion in Eden et al.’s analysis using integrated stage (14%).  
We agree that “international comparisons must understand the source of the data”. The ICBP 
studies have confirmed the need for better communication between clinicians and cancer 
registries. Cancer registries must be able to record systematically whether ‘integrated’ stage 
is truly integrated, or whether the origin of the component stage variables is simply unknown. 
Better international guidance is required for cancer registries on how to collect, prioritise and 
code data on stage at diagnosis. These points have been made in every paper that has 
emerged from the ICBP collaboration.  
Given the quality of the available data, we find it difficult to imagine what else could have 
been done to improve the quality of the analyses on population-based cancer survival by 
stage at diagnosis, or the robustness of the interpretation of the findings. 
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COLON Pathological Clinical Unknown Pathological Clinical Unknown Pathological Clinical Unknown
Canada b 93.7 99.9 85.6 7.1 0.0 82.5 11.9 0.0 11.4 88.6 0.0
Denmark b 80.0 100.0 0.0 0.0 91.8 0.0 0.0 89.1 0.0 0.0 100.0
Sweden 96.6 30.1 0.0 0.0 92.8 0.0 0.0 91.1 0.0 0.0 100.0
UK 72.2 17.2 28.3 15.4 27.8 30.4 16.2 26.9 32.7 35.1 32.2
RECTUM
Canada b 74.5 99.4 74.7 20.9 0.0 72.4 22.9 0.0 24.3 75.7 0.0
Denmark b 76.7 100.0 0.0 0.0 94.5 0.0 0.0 89.8 0.0 0.0 100.0
Norway c 70.0 0.0 - - - - - - - - -
Sweden 90.2 33.9 0.0 0.0 92.2 0.0 0.0 90.2 0.0 0.0 100.0
UK 69.4 18.8 31.1 13.0 29.3 32.2 14.5 28.7 31.1 34.1 34.8
a Final proportions of all patients for whom a valid stage category could be obtained from the raw data
b Patients diagnosed in 2004-7
c Final stage defined solely from Dukes' stage information: no component T, N and M codes available
Origin of 'N' code Origin of 'M' code
Table 1: Origin of stage variable for patients included in survival analyses of the ICBP study: colon and rectal cancer patients diagnosed during 2000-7
Dukes' stage value derived 
from T, N, M (%)
Valid Dukes' 
stage (%) a
of 
which
of 
which
Origin of 'T' code
Number A B C D
Eden et al. "ICBP-like" 2,406       22 37 39 2
Integrated 2,406       21 33 32 14
Maringe et al.
a
Final 102,555   9.4 38.6 35.1 16.9
T, N and Mb 17,650  4.4 20.4 18.1 57.2
Dukesc 84,905  10.5 42.4 38.7 8.5
Final 46,769     20.7 28.6 33.8 16.9
T, N and M
b
8,808    11.7 17.8 22.1 48.4
Dukes
c
37,961  22.8 31.1 36.5 9.6
a
 Observed stage distributions; imputation of missing stage values did not alter the distribution much
b Restriction to patients whose final stage was derived from the component T, N and M values
c Retsriction to patients whose final stage was derived from the raw Dukes' stage variable
Colon and rectum 
combined
Colon
Rectum
Dukes' stage
Table 2: Comparisons of stage distribution (%) in the UK, by source
